RXRX Recursion Pharmaceuticals, Inc.

NASDAQ
$3.74

Recursion Pharmaceuticals, Inc. (RXRX) is expected to report earnings on November 9, 2026, before the market open. The consensus earnings estimate is a loss of $0.24 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +21.4% since its last earnings release on August 5, 2026.

Recursion Pharmaceuticals Missed Consensus Estimates
Wednesday, August 5, 2026 · 6:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 6:30 AM ET
Earnings Whisper
-
vs ($0.24)
Rev est $8.42M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $3.49

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Recursion Pharmaceuticals, Inc.

Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery.

Sector

Healthcare

Industry

Biotechnology

Held By 4 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.